🔥 Melanoma: INTerpath-001 embargo lifts early at ESMO26: RFS HR 0.58, DMFS HR 0.62 (LBA1 abstract)

🔬 What's Hot in Hematology/Oncology — KOL Pulse Daily Digest (Oct 23)

"🚨 #ESMO26 INTerpath-001 leaked before the embargo, so @myESMO released it early

➡️ Intismeran (mRNA-4157) + pembro vs placebo + pembro, adjuvant stage IIB-IV #melanoma

• 24-mo RFS 82.2% vs 70.0% | HR 0.58
• 24-mo DMFS 88.5% vs 80.2% | HR 0.62
• G≥3 AEs 23.6% vs 20.3%" — @YGaritaonaindia

🫁 Lung: Sunvozertinib reaches US patients; DeLLphi-304 OS benefit holds
🎗️ Breast: NATALEE 6-year OS, TALENT, PANKU-Breast01 and the PATINA FDA–EMA split
🔵 GI: RASolute 302 subgroups, SANO 5-year and G-HOPE-001 open ESMO26 GI
🔷 GU: European Commission approves perioperative EV + pembrolizumab regardless of cisplatin eligibility (FDA-approved Jul 10, 2026)
🟣 Myeloma: IMF launches US Myeloma Network; bispecific toxicity and MRD-stop debates
🩸 Heme: Legend's in vivo CAR-T IND; EHA follicular lymphoma guideline shift
🏛️ FDA: Keytruda + Keytruda Qlex TMB-H solid-tumor approval converted to traditional; TMB cutoff raised from ≥10 to ≥13 mut/Mb

Full story, verbatim KOL quotes + sources 👉 https://hubs.ly/Q04C6PBt0